KaloBios Pharmaceuticals Inc (NASDAQ:KBIO)

0.64
Delayed Data
As of 11:48am ET
 +0.0949 / +17.41%
Today’s Change
0.36
Today|||52-Week Range
3.69
-63.01%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$18.0M

Company Description

KaloBios Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of monoclonal antibody therapeutics. It develops a portfolio of proprietary and patient-targeted monoclonal antibodies designed to treat severe life-threatening or debilitating diseases for which there is an unmet medical need, with a clinical focus on severe respiratory diseases and cancer. The company's antibody technology, Humaneered, treats serious medical conditions with a primary clinical focus on respiratory diseases and cancer. KaloBios Pharmaceuticals was founded on March 15, 2000 and is headquartered in South San Francisco, CA.

Contact Information

KaloBios Pharmaceuticals, Inc.
260 East Grand Avenue
South San Francisco California 94080
P:(650) 243-3100
Investor Relations:

Employees

Shareholders

Individual stakeholders32.64%
Other institutional28.39%
Mutual fund holders22.04%

Top Executives

Herbert C. CrossChief Executive & Financial Officer
Geoffrey Thomas YarrantonCSO, Executive VP-Research & Development
Néstor A. MolfinoChief Medical Officer
Harry LamSenior Vice President-Technical Operations
Anne Borgman HageyAssociate Chief Medical Officer

To view my watchlist

Not a member yet?

Sign up now for a free account